Enzalutamide-induced “BRCAness” and PARP inhibition is a synthetic lethal therapy for castration-resistant prostate cancer

Cancers with dysfunctional mutations in BRCA1 or BRCA2, most commonly associated with some breast cancers, are deficient in the DNA damage repair pathway called homologous recombination (HR), which makes them exquisitely vulnerable to poly(ADP-ribose) polymerase (PARP) inhibitors, such as olaparib....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Signal
Main Authors: Li, Likun, Karanika, Styliani, Yang, Guang, Wang, Jiangxiang, Park, Sanghee, Broom, Bradley, Manyam, Ganiraju C., Wu, Wenhui, Luo, Yong, Basourakos, Spyridon, Song, Jian H., Gallick, Gary E., Karantanos, Theodoros, Korentzelos, Dimitrios, Azad, Abul Kalam, Kim, Jeri, Corn, Paul G., Aparicio, Ana M., Logothesis, Christopher J., Troncoso, Particia, Timothy, Heffernan, Toniatti, Carlo, Lee, Hyun-Sung, Lee, Ju-Seog, Zuo, Xuemei, Chang, Wenjun, Yin, Jianhua, Thompson, Timothy C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5855082/
https://ncbi.nlm.nih.gov/pubmed/28536297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scisignal.aam7479
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados